Oncoinvent ASA

Share Issue/Capital Change • Dec 22, 2025

Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oslo, Norway, 22 December 2025: Oncoinvent ASA ("Oncoinvent" or the "Company")

(OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing

innovative treatments for solid cancers, today announce that the Board of

Directors has granted options to employees.

As previously communicated and with the objective of aligning share option

participants' interests with those of the shareholders of the Combined Company,

the Board of Directors has established a replacement share option and RSU

program for employees and board members similar to Oncoinvent's program before

the merger with BerGenBio. This has been transformed by using the exchange ratio

in the merger and adjusting the strike to secure a value neutral transition.

Following this, a total of 6,355,096 share options has been granted as

replacement for the previous option program, of which 4,451,133 to primary

insiders. See the attached forms.

Options granted under the share option program will normally vest equally over a

four-year period from the date of grant and each option, when exercised, will

give the right to receive one share in the Company at a fixed strike price set

at time of grant. Options granted under the share option program expire seven

years after grant date.

In addition, a total of 25,770,000 new share options were granted, equal to 5.4%

of fully diluted shares in the Company. Total options outstanding after this

grant are 32,125,096, equal to 6.7% of fully diluted shares in the Company. The

strike price for this grant is NOK 0.50 per option equal to the volume weighted

average share price the last day before the grant, limited to nominal value of

the shares. Of the total grant, 15,500,000 share options were granted to primary

insiders of the Company (total holdings of share options following this grant

and replacement program):

Øystein Soug - CEO: 5,000,000 (6,106,466)

Kari Myren - CMO: 2,000,000 (2,358,399)

Anne-Kirsti Aksnes - CCO: 2,000,000 (2,336,751)

Gro Hjellum - COO: 2,000,000 (2,334,826)

Kristine Lofthus - CPO: 1,500,000 (1,829,534)

Stian Brekke - Head of RA:  1,500,000 (1,828,813)

Anne Cecilie Alvik - Head of QA: 1,500,000 (1,828,452)

Share options issued to the board as part of the replacement option program

following the merger:

Gillies O'Bryan-Tear (Chairperson of the Board): 353,722

Kari Grønås (Board member): 165,168

Hilde Steineger (Board member): 165,168

Orlando Oliveira (Board member): 165,168

Johan Häggblad (Board member): 95,012

The board considers an option program as an important element in attracting and

retaining employees to foster long-term success. The board considers the option

program terms and allocation to be at the market for comparable peers.

PDMR notifications of transactions: replacement

options (https://mb.cision.com/Public/15728/4285903/8cd75ccb730cd061.pdf)

PDMR notifications of transactions: new

grants (https://mb.cision.com/Public/15728/4285903/81db31dd23e60ae6.pdf)

This information is subject to the disclosure requirements pursuant to article

19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting

micro-metastases post-surgery, harnessing the benefits of modern

radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical

development program in two indications. One Phase 1 trial and one Phase 1/2a

trial have been completed and one randomized Phase 2 trial is currently ongoing

in the US, UK and Europe. Early clinical efficacy data are highly encouraging,

and no serious toxicity or safety concerns have been reported to date. The

Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art

manufacturing facility to produce drug products for clinical trials in Nydalen,

Oslo. Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local

treatment of cancer that has spread to body cavities. It consists of calcium

carbonate microparticles containing the radioactive material radium-224. The

mode of action is the decay of radium-224 emitting alpha-particles, a highly

potent form of ionizing radiation. Radspherin® is investigated in clinical

studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer

and it is administered intraperitoneally after surgical resection with removal

of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press

release are forward-looking statements and are not a representation that

Oncoinvent's plans, estimates, or expectations will be achieved. These forward

-looking statements represent Oncoinvent's expectations as of the date of this

press release, and Oncoinvent disclaims any obligation to update the forward

-looking statements. These forward-looking statements are subject to known and

unknown risks and uncertainties that may cause actual results to differ

materially, including with respect to whether the results of clinical or other

studies will support the use of our product offerings, the impact of results of

such studies, our expectations of the reliability, accuracy and performance of

our tests, or of the benefits of our tests and product offerings to patients,

providers and payers.